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Summary
Objectives: Shigellosis remains a major public health problem in developing countries. Anti-
microbial resistance has complicated the empirical treatment. Knowledge of serotypes is crucial
in vaccine development, as cross-protection between various serotypes is limited. Therefore we
conducted a prospective study to determine the frequency of isolation of Shigella serotypes and
antimicrobial resistance.
Methods: Stool samples from 8155 individuals, collected through a surveillance study conducted
in four slums of Karachi from January 2002 to March 2004, were cultured. Results: Shigella was
isolated in 394 (4.8%) of 8155 patients presenting with diarrhea. Two hundred and forty-two (62%)
isolates were Shigella flexneri, 72 (18%) were Shigella sonnei, 43 (11%) were Shigella boydii, and
37 (9%) were Shigella dysenteriae. Thirteen S. flexneri serotypes were identified, of which the
most frequent were 2a (38), 6 (37), and 1b (25), followed by 2b (23). Only 22 (5.6%) Shigella
isolates were found to be pan-susceptible. Large proportions of isolates were resistant to co-
trimoxazole (89% S. flexneri, 81% S. dysenteriae, 80% S. sonnei, and 56% S. boydii) and ampicillin
(87% S. flexneri, 68% S dysenteriae, 35% S. boydii, and 4% S. sonnei).
Conclusions: Concurrent circulation of multiple strains with high resistance is worrying and
mandates surveillance at the national level to facilitate the control of shigellosis.
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Shigellosis, an acute invasive enteric infection caused by
Shigella, is recognized as a major public health problem.1—3
Ninety-nine percent of shigellosis episodes occur in developing
countries. The majority of cases and of deaths occur among
children less than five years of age.1
Serological analysis of Shigella has long been used to
characterize isolates for epidemiological and diagnostic pur-
poses.4,5 The genus is divided into four serogroups with 47
serotypes: A (S. dysenteriae, 12 serotypes), B (S. flexneri, 15
serotypes), C (S. boydii, 18 serotypes), and D (S. sonnei, one
antigenic type, phase 1 and phase 2). For the development of
vaccine-based control strategies it is essential to understand
the prevalent serotypes, since immunity against shigellosis is
serotype-specific.6—10 The prevalence of a particular species
of Shigella differs in various geographical areas. In 1999
Kotloff and coworkers reported S. flexneri as the main
serogroup found in developing countries (60%), followed by
S. sonnei (15%), and S. dysenteriae and S. boydii with equal
frequencies (6%).6 However, data consistently demonstrate
that S. sonnei is the most common serogroup found in indus-
trialized countries (77%), followed by S. flexneri (16%), S.
boydii (2%), and S. dysenteriae (1%).6
A definitive diagnosis of shigellosis can be made by iso-
lating the organism from stool. It is one of the few enteric
infections for which antimicrobials are prescribed. Antimi-
crobial resistance has complicated the selection of empirical
agents for its treatment.1,2,11—15 Also, antimicrobial resis-
tance amongst Shigella species varies from region to
region.16—18 Previously effective drugs such as tetracycline,
ampicillin, and co-trimoxazole have become largely ineffec-
tive, and the recent emergence of resistance against nali-
dixic acid has further narrowed the choice of effective
agents.14—16 For the choice of an appropriate antibiotic it
is important to understand the local antimicrobial resistance
patterns. An understanding of serogroups and serotypes is
crucial in vaccine development, as cross-protection between
various Shigella serotypes is very limited. In preparation for a
vaccine trial we conducted surveillance in four urban slums of
Karachi. We report herein the frequency of distribution of
various serogroups and serotypes of Shigella, as well as local
susceptibility patterns.
Materials and methods
Four slum communities (Rehri Goth, Sherpao Colony, Sulta-
nabad, and Hijrat Colony) located in Karachi, Sindh Pro-
vince, Pakistan were included in this surveillance study.
Rehri Goth and Sherpao Colony are in the southeast of
Karachi. Hijrat Colony and Sultanabad, two contiguous
urban slums, are near the business center and port of
Karachi. In 2002 the combined catchment area for this
surveillance study had a population of 59 584, of which
8381 (14%) were children under the age of five years. In
each of the four communities a treatment center was estab-
lished for the purpose of surveillance. A passive surveillance
was conducted at these treatment centers by enrolling all
patients visiting the study clinics.
Households of patients enrolled at surveillance clinics
were visited weekly, and the head or a representative was
asked about diarrhea cases in members of the household inthe preceding 7 days. If a diarrhea case was reported, the
patient was asked to come to the study clinic. Consenting
patients of all age groups with diarrhea or dysentery pre-
senting to the study clinics were eligible to participate in the
study. For every patient presenting with diarrhea, a case
report form (CRF) describing demographics and medical
history was completed, and two rectal/stool swabs or stool
specimens were obtained. All consenting patients with a
history of dysentery or diarrhea for three days or more were
eligible for study enrollment. Stool samples or rectal swabs
from patients presenting between January 2002 and March
2004 were included in the analysis. All samples were pro-
cessed in the Clinical Microbiology Laboratory of the Aga
Khan University Hospital.
Two specimens, either rectal swabs or stool, were
obtained from each patient with diarrhea. Specimens were
immediately placed in buffered glycerol saline (BGS) and
transported to the clinical laboratory in a cool box. On
arrival, specimens were plated on MacConkey and Salmo-
nella—Shigella agar. For enrichment, samples were also
inoculated into selenite-F broth and were incubated at
37 8C for 24 h in an aerobic environment. After overnight
incubation, selenite-F broth was further subcultured on Sal-
monella—Shigella agar (Oxoid). Biochemical reactions of
suggested lactose non-fermenters and oxidase-negative colo-
nies were evaluated in triple sugar iron, urea, lysine, indole,
and motility medium. Colonies were serologically confirmed
by slide agglutination with appropriate group-specific poly-
valent antisera, followed by type-specific monovalent anti-
sera (Denka-Seiken, Tokyo, Japan). Non-serotypable isolates
were further checked by API20E (BioMerieux, France). Anti-
biotic susceptibility testing was performed by Kirby—Bauer
disk diffusion method, against ampicillin (10 mg), chloram-
phenicol (30 mg), ceftriaxone (30 mg), co-amoxyclav (30 mg),
co-trimoxazole (25 mg), nalidixic acid (30 mg), and ofloxacin
(5 mg).19 Escherichia coli ATCC strain 25922 was used as the
control.
Data management and analysis
All results were double-entered into custom-made data entry
programs (FoxPro, Microsoft, Redmond, WA, USA). The data
management programs included error as well as consistency
and range check programs. Statistical analysis was done using
SPSS version 14.0 for Windows (SPSS Inc., Chicago, IL, USA). A
p-value of less than 0.05 was considered significant.
Ethics
Verbal consent was obtained from each participant (parent or
guardian for children) following an explanation of the pur-
pose of the study. The study received approval from the Aga
Khan University Ethics Committee and from the Secretariat
Committee for Research Involving Human Subjects, World
Health Organization, Geneva, Switzerland.
Results
During the study period, a total of 8155 stool samples were
received and 394 specimens were found to be positive for
Shigella species, giving an average isolation rate of 4.8%. Two
Figure 2 Antimicrobial resistance in Shigella isolates in Kar-
achi, Pakistan (AMC, co-amoxyclav; NA, nalidixic acid; SXT, co-
trimoxazole; AMP, ampicillin; OFX, ofloxacin; C, chlorampheni-
col).
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(18%) were S. sonnei, 43 (11%) were S. boydii, and 37 (9%)
were S. dysenteriae.
The percentage of S. flexneriwas 67% in Rehri Goth, 65% in
Sultanabad, 58% in Sherpao, and 54% in Hijrat Colony. Thir-
teen S. flexneri serotypes were identified, of which the most
frequent were 2a (38), 6 (37), and 1b (25), followed by 2b
(23). S. sonnei phase 1 (56/72) was the most prevalent sero-
subtype. Eleven serotypes were found in S. boydii and the
most frequent isolates were S. boydii 1, 2, and 8. Eight
serotypes were identified in S. dysenteriae and the most
prevalent subtype was 7 (9/37); Figure 1.
Overall 78 (20%) isolates suggestive of Shigella (groups A—
D) by biochemical reactions, conventional as well as API20E,
and serology could not be further subtyped and remained
untypable (S. flexneri 64/242 (26%), S. boydii 5/43 (12%), S.
dysenteriae 6/37 (16%), and S. sonnei 3/72 (04%); Figure 1.
Among all isolates, only 22 (5.6%) were found to be pan-
susceptible. Large proportions of isolates were resistant to
co-trimoxazole (81% S. flexneri, 81% S. dysenteriae, 75% S.
sonnei, and 56% S. boydii) and ampicillin (87% S. flexneri, 68%
S. dysenteriae, 35% S. boydii, and 4% S. sonnei); Figure 2.
Forty-two percent of isolates were resistant to both drugs
(co-trimoxazole and ampicillin). The frequency of isolation of
multidrug-resistant isolates in individual groups was 76% in S.
flexneri, 62% in S. dysenteriae, 26% in S. boydii, and 4% in S.
sonnei.
Resistance to chloramphenicol was common in S. flexneri
(50%), S. dysenteriae (41%), and S. boydii (28%), but very low
in S. sonnei (3%). Low resistance was found to co-amoxyclav
(25% S. flexneri, 12% S. dysenteriae, 10% S. boydii, and 5% S.Figure 1 Frequency of isolation of various serosonnei). Nalidixic acid resistance was variable, with S. sonnei
(13%) having the highest rate of resistance followed by S.
dysenteriae, S. flexneri (3%), and S. boydii (2%); Figure 2.
Very low resistance was found to ofloxacin (0% S. dysenteriae,
3% S. flexneri, 2% S. boydii, and 7% S. sonnei). None of the
isolates were ceftriaxone-resistant.
When tested for average resistance to all antibiotics
(ampicillin, co-trimoxazole, nalidixic acid, chloramphenicol,
co-amoxyclav, nalidixic acid, and ofloxacin), S. flexneri was
the most resistant and S. sonnei was the most susceptible
group to all tested drugs — 41% (out of 242 isolates) versus
18% (out of 72 isolates) with a p value of 0.0001. S.
dysenteriae was the second most resistant species and S.
boydii was the next, with rates of 34% and 22%, respectively.types of Shigella species in Karachi, Pakistan.
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This is the first study reporting the prevalence of Shigella
serotypes in Karachi, Pakistan. We report an isolation rate of
4.8%, which is similar to other studies published in India
(7.7%) and Nepal (4%).16,17 S. flexneri was most frequently
isolated, which is consistent with previous reports on Shigella
prevalence in resource-limited countries.1,6
The distribution of Shigella serogroups flexneri, boydii,
and dysenteriae was highly heterogeneous. Furthermore, a
substantial number of Shigella isolates were untypable.
Emergence of new subtypes is common in Shigella spe-
cies.20—22 Recently Woodward et al. in Canada and Grimont
et al. in France reported new serotypes of Shigella boy-
dii.23,24 A change in the trend and emergence of new ser-
otype 1c has also been reported from Bangladesh.25
These findings highlight the importance of continuous
monitoring of emerging isolates. However identification of
these isolates requires specific antisera and molecular typ-
ing, which remain beyond the capability of the majority of
clinical diagnostic laboratories in developing countries.25
There may well be a need to establish a reference molecular
laboratory at a national level.
Various studies have reported an increase in antimicrobial
resistance amongst different species of Shigella against com-
monly used drugs, including ampicillin, tetracycline, chlor-
amphenicol, and co-trimoxazole.11—16,26—28 This study also
reveals a very high rate of resistance, particularly against co-
trimoxazole and ampicillin. Resistance to individual drugs is
very high in S. flexneri in comparison to earlier reports (7% to
co-trimoxazole and 10% to ampicillin) from Pakistan pub-
lished in 1998 and 2003.29,30 These results strongly suggest
that ampicillin and co-trimoxazole can no longer be used
empirically in cases of severe diarrhea and dysentery in
Karachi. It is very likely that high antimicrobial resistance
is the direct outcome of irrational use and ready over-the-
counter availability of antibiotics including ampicillin and co-
trimoxazole in the community.
The relative antimicrobial resistance of various Shigella
species may vary geographically. We found statistically sig-
nificant differences in the antimicrobial susceptibility of S.
flexneri and S. sonnei strains. This is in contrast to reports
published from Israel and Bangladesh, but consistent with
observations in several other countries.31—36
Resistance to nalidixic acid has previously been reported
from Iran, Hong Kong, Vietnam, China, Chile, and also from
neighboring India.29,34—38 We found variable resistance in
different Shigella serogroups. No nalidixic acid resistance
was observed in Bangladesh in 1985, increasing to 100%
resistance in 1997.14 In Pakistan, nalidixic acid is an inexpen-
sive and frequently used drug for community-acquired diar-
rhea. Resistance to nalidixic acid is distressing, as acquiring
resistance against nalidixic acid in a resource-limited country
will make the treatment options for family physicians and
pediatricians more difficult and costly.
Fluoroquinolone resistance has been reported from the
neighboring countries of India and Iran.16,28 The emergence
of fluoroquinolone resistance, though very low at present, is
alarming, as resistant enteric organisms disseminate quickly
in compromised hygienic and living conditions. Fortunately,
no resistance was found against third-generation cephalos-
porin, which is consistent with the international data. In2003, a report published from the northern part of Pakistan
stated that 10% of Shigella isolates were sensitive to all
antimicrobials.30 We found the scenario has further wor-
sened, as only 5.6% of our isolates remained pan-susceptible.
In conclusion, the present study demonstrates that S.
flexneri is currently the predominant species in Karachi,
Pakistan. Antimicrobial resistance patterns suggest wide-
spread resistance of Shigella to multiple clinically relevant
antimicrobials. Recommendations on antimicrobial treat-
ment must be regularly updated based on surveillance
results.
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